Evidence map›Paper›PMID 42707328›Full record

ArticleFrontiers in oncology2026

Pretreatment TyG-BMI predicts CD19 CAR-T persistence and prognosis in diffuse large B-cell lymphoma.

Zelin Liu, Ruijun Yang, Jiawen Chen, Ziyu Liu, Yangyang Ding, Keke Huang, Ya Liao, Linhui Hu, Lianfang Pu, Lujie Liu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zelin Liu *Hematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Ruijun Yang *Hematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Jiawen ChenHematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Ziyu LiuHematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Yangyang DingDepartment of Hematology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Keke HuangHematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Ya LiaoHematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Linhui HuDepartment of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Lianfang PuDepartment of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Lujie LiuWeifang Yidu Central Hospital, Qingzhou, Shandong, China.
Jiyu WangHematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Qianshan TaoHematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Shudao XiongHematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although CD19 CAR-T cell therapy has improved outcomes in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), responses are variable and predictive biomarkers are lacking. The triglyceride glucose-body mass index (TyG-BMI)-a surrogate of insulin resistance-has shown prognostic value in solid tumors, but its relevance to DLBCL and CAR-T efficacy remains unknown. Methods: We retrospectively analyzed 204 newly diagnosed DLBCL patients treated with rituximab-containing regimens, stratified by median TyG-BMI. Prognostic associations were assessed by Kaplan-Meier and multivariate Cox regression, and a nomogram was constructed. In an exploratory sub-analysis, 20 patients who received CD19 CAR-T therapy were assessed. CAR-T cell persistence was measured by flow cytometry one week post-infusion and correlated with pre-infusion TyG-BMI by Pearson analysis. CRS and ICANS were graded per ASTCT criteria. Post-CAR-T survival was compared by Kaplan-Meier analysis stratified by median pre-infusion TyG-BMI. Results: High TyG-BMI was independently associated with poorer PFS (HR, 2.146; 95% CI, 1.092-4.214; Conclusion: TyG-BMI is an independent prognostic factor in DLBCL that refines IPI-based stratification, and elevated pre-infusion TyG-BMI is associated with attenuated CAR-T cell persistence and inferior outcomes. This readily available metabolic index may aid risk assessment and treatment planning in DLBCL.

Indexed as

CD19 CAR-Tdiffuse large B cell lymphomaPre-treatment assessmentPrognostic modelTriglyceride glucose-body mass index

Identifiers

PMID42707328
PMCPMC13547084

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.